Access our archived eMedical Forum Webcasts, which are available for your viewing at any time.
Please sign in using the form to the left to access this service.
Important Product Information
IMPORTANT INFORMATION:
SINGULAIR is indicated for prophylaxis and chronic treatment of asthma in patients 12 months and older.
SINGULAIR should not be used as rescue medication to treat acute asthma episodes. Patients should be advised to have appropriate rescue medication available.
Use of SINGULAIR may not eliminate the need for inhaled or systemic corticosteroids. Patients should not decrease the dose or stop taking any other anti-asthma medications unless instructed by a physician.
Safety and effectiveness of SINGULAIR in patients younger than 12 months have not been established.
Patients should be advised that, while using SINGULAIR, medical attention should be sought if short-acting inhaled bronchodilators are needed more often than usual or if more than the maximum number of inhalations of short-acting bronchodilator treatment prescribed for a 24-hour period are needed.
COZAAR and HYZAAR are registered trademarks of E.I. du Pont de Nemours and Company, Wilmington, Delaware, USA
FOSAMAX PLUS D is a trademark of Merck & Co., Inc.
VYTORIN and ZETIA are registered trademarks of MSP Singapore Company, LLC. View the Merck/Schering-Plough privacy policy.
All other brand names are registered trademarks of Merck & Co., Inc.
MerckServices and MerckSource are registered trademarks of Merck & Co., Inc.
MerckProductServices and MerckMedicus are trademarks of Merck & Co., Inc.
Contact Us
Ask a Product-Related Question or Report an Adverse Event
Let us assist you with information and services related to Merck and its products. Get Started
requires a 
requires a 
_2007_NIH_Guidelines_Image.jpg)
2007 NIH Asthma Guidelines
ATAQ Questionnaire for Children and Teens
ATAQ Questionnaire for Adult
ATAQ Questionnaire for Children and Teens - Spanish
ATAQ Questionnaire for Adult - Spanish
SINGULAIR® (montelukast sodium) For Asthma
